What is ORF Genetics?
Based in Iceland, ORF Genetics operates at the intersection of molecular biology and industrial biotechnology. The company has pioneered a proprietary barley-based expression system, which serves as a sustainable and scalable platform for the production of high-purity, animal-free recombinant growth factors and cytokines. This technological innovation is essential for several high-growth verticals, including stem cell research, regenerative medicine, the emerging cultivated meat industry, and advanced dermatological skincare formulations. By eliminating animal-derived components, ORF Genetics addresses a critical bottleneck in biomanufacturing, offering a cleaner, more consistent alternative for researchers and commercial manufacturers alike.
How much funding has ORF Genetics raised?
ORF Genetics has raised a total of $5.8M across 1 funding round:
Other Financing Round
$5.8M
Other Financing Round (2025): $5.8M, investors not publicly disclosed
Key Investors in ORF Genetics
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for ORF Genetics?
With this major enterprise-level funding, ORF Genetics is poised to transition from a specialized biotech innovator to a dominant player in the global recombinant protein market. The strategic roadmap likely involves scaling its barley-based production infrastructure to meet the surging demand from the cultivated meat sector, which requires cost-effective, high-quality growth factors to achieve price parity with conventional proteins. Furthermore, the company is expected to deepen its research and development efforts in regenerative medicine, leveraging its unique expression platform to support clinical-grade applications. As the firm continues to refine its proprietary technology, it remains a key entity to watch for potential partnerships with global pharmaceutical and food-tech conglomerates seeking to optimize their supply chains with sustainable, animal-free inputs.
See full ORF Genetics company page
